Search

Your search keyword '"Corradini, Nadege"' showing total 19 results
Start Over Author "Corradini, Nadege" Publisher elsevier ltd
19 results on '"Corradini, Nadege"'

1. Alveolar soft part sarcomas in young patients: The French national NETSARC+ network experience

Author

Genevois, Anne-Laure, Carton, Matthieu, Jean-Denis, Myriam, Cyrta, Joanna, Corradini, Nadège, Metayer, Lucy, Chemin-Airiau, Claire, Karanian, Marie, Dufresne, Armelle, Pannier, Stéphanie, El Zein, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Gantzer, Justine, Honoré, Charles, Noal, Sabine, Héritier, Sébastien, Guillemet, Cécile, Serre, Jill, Le Loarer, François, Pierron, Gaëlle, Merlin, Marie-Sophie, Anract, Philippe, Gomez-Mascard, Anne, Llacer, Carmen, Ducimetière, Françoise, Toulmonde, Maud, Blay, Jean-Yves, and Orbach, Daniel

Published
2024
Full Text
View/download PDF

2. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

Author

Chaix, Jordane, Schleiermacher, Gudrun, Corradini, Nadège, André, Nicolas, Thebaud, Estelle, Gambart, Marion, Defachelles, Anne-Sophie, Entz-Werle, Natacha, Chastagner, Pascal, De Carli, Émilie, Ducassou, Stéphane, Landman-Parker, Judith, Adam-de-Beaumais, Tiphaine, Larive, Alicia, Michiels, Stefan, Vassal, Gilles, Valteau-Couanet, Dominique, Geoerger, Birgit, and Berlanga, Pablo

Published
2024
Full Text
View/download PDF

3. Leiomyosarcoma and liposarcoma in young patients: The national netsarc+ network experience

Author

Genevois, Anne-Laure, Carton, Matthieu, Jean-Denis, Myriam, Cyrta, Joanna, Corradini, Nadège, Berlanga, Pablo, Chemin-Airiau, Claire, Honore, Charles, El Zein, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Anract, Philippe, Gantzer, Justine, Karanian, Marie, Rome, Angélique, Duffaud, Florence, Chevreau, Christine, Watson, Sarah, Le Cesne, Axel, Llacer, Carmen, Le Loarer, François, Pierron, Gaëlle, Gouin, François, Gomez-Mascard, Anne, Causeret, Sylvain, Ducimetière, Françoise, Kalbacher, Elsa, Toulmonde, Maud, Blay, Jean-Yves, and Orbach, Daniel

Published
2023
Full Text
View/download PDF

4. The role of cancer predisposition syndrome in children and adolescents with very rare tumours

Author

Orbach, Daniel, Brecht, Ines B., Corradini, Nadege, Bouchoucha, Yassine, Roganovic, Jelena, Bourdeaut, Franck, Reguerre, Yves, Kuiper, Roland P., Bressac de Paillerets, Brigitte, Ferrari, Andrea, Virgone, Calogero, Godzinski, Jan, Bisogno, Gianni, Guerrini-Rousseau, Lea, Farinha, Nuno Jorge, Bergamaschi, Luca, Bien, Ewa, Kuhlen, Michaela, Schneider, Dominik T., and Ben Ami, Tal

Published
2023
Full Text
View/download PDF

5. Outcomes in lung-only metastatic rhabdomyosarcoma: An analysis of data from the European paediatric Soft tissue sarcoma Study Group MTS 2008 study

Author

Chisholm, Julia C., Schoot, Reineke A., Cameron, Alison L., Casanova, Michela, Minard-Colin, Veronique, Coppadoro, Beatrice, Garrido, Marta, Rogers, Timothy, Orbach, Daniel, Glosli, Heidi, Ben-Arush, Miriam, Ferman, Sima, Scarzello, Giovanni, van Rijn, Rick R., Hladun, Raquel, Corradini, Nadege, Ferrari, Andrea, Jenney, Meriel, Bisogno, Gianni, and Merks, Johannes H.M.

Published
2023
Full Text
View/download PDF

6. Risk factors in pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST): Results from the French Pediatric Oncology Society (SFCE) cohort

Author

Chaix, Jordane, Karanian, Marie, Corradini, Nadège, Merched, Maria, Larousserie, Frédérique, Galmiche, Louise, Lacour, Brigitte, Marie-Cardine, Aude, Defachelles, Anne-Sophie, Berlanga, Pablo, Rome, Angélique, Thébaud, Estelle, Bernier-Chastagner, Valérie, Brisse, Hervé J., Hameury, Frédéric, Wolkenstein, Pierre, Ducassou, Stéphane, Orbach, Daniel, and Vérité, Cécile

Published
2023
Full Text
View/download PDF

7. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age

Author

Bouttefroy, Séverine, Penel, Nicolas, Orbach, Daniel, Minard-Colin, Véronique, Le Cesne, Axel, Blay, Jean-Yves, Marec-Berard, Perrine, Verité, Cécile, Laurence, Valérie, Piperno-Neumann, Sophie, Defachelles, Anne-Sophie, Bompas, Emmanuelle, Chevreau, Christine, Duffaud, Florence, Salas, Sébastien, Morelle, Magali, Jean-Denis, Myriam, Italiano, Antoine, Bonvalot, Sylvie, and Corradini, Nadège

Published
2023
Full Text
View/download PDF

8. Locally aggressive rarely metastazing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network

Author

Brisset, Claire, Carton, Matthieu, Chemin-Airiau, Claire, Karanian, Marie, Vérité, Cécile, Corradini, Nadege, Mascard, Eric, Gouin, François, Bonvalot, Sylvie, Minard-Colin, Véronique, Fayard, Cindy, Pannier, Stéphanie, Blay, Jean-Yves, Le Nail, Louis-Romée, Le Loarer, François, Brisse, Hervé J., Chotel, Franck, Pierron, Gaëlle, Tirode, Franck, Defachelles, Anne-Sophie, Toulmonde, Maud, and Orbach, Daniel

Published
2022
Full Text
View/download PDF

10. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study

Author

Geoerger, Birgit, Zwaan, C Michel, Marshall, Lynley V, Michon, Jean, Bourdeaut, Franck, Casanova, Michela, Corradini, Nadège, Rossato, Gianluca, Farid-Kapadia, Mufiza, Shemesh, Colby S, Hutchinson, Katherine E, Donaldson, Francis, Liao, Minlei, Caron, Hubert, and Trippett, Tanya

Published
2020
Full Text
View/download PDF

12. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Author

Gaspar, Nathalie, Occean, Bob-Valéry, Pacquement, Hélène, Bompas, Emmanuelle, Bouvier, Corine, Brisse, Hervé J., Castex, Marie-Pierre, Cheurfa, Nadir, Corradini, Nadège, Delaye, Jessy, Entz-Werlé, Natacha, Gentet, Jean-Claude, Italiano, Antoine, Lervat, Cyril, Marec-Berard, Perrine, Mascard, Eric, Redini, Françoise, Saumet, Laure, Schmitt, Claudine, Tabone, Marie-Dominique, Verite-Goulard, Cécile, Le Deley, Marie-Cécile, Piperno-Neumann, Sophie, and Brugieres, Laurence

Published
2018
Full Text
View/download PDF

14. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial

Author

Piperno-Neumann, Sophie, Le Deley, Marie-Cécile, Rédini, Françoise, Pacquement, Hélène, Marec-Bérard, Perrine, Petit, Philippe, Brisse, Hervé, Lervat, Cyril, Gentet, Jean-Claude, Entz-Werlé, Natacha, Italiano, Antoine, Corradini, Nadège, Bompas, Emmanuelle, Penel, Nicolas, Tabone, Marie-Dominique, Gomez-Brouchet, Anne, Guinebretière, Jean-Marc, Mascard, Eric, Gouin, François, Chevance, Aurélie, Bonnet, Naïma, Blay, Jean-Yves, and Brugières, Laurence

Published
2016
Full Text
View/download PDF

15. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)

Author

Minard-Colin, Véronique, Ichante, Jean-Laurent, Nguyen, Laurent, Paci, Angelo, Orbach, Daniel, Bergeron, Christophe, Defachelles, Anne-Sophie, André, Nicolas, Corradini, Nadège, Schmitt, Claudine, Tabone, Marie-Dominique, Blouin, Pascale, Sirvent, Nicolas, Goma, Gisele, Geoerger, Birgit, and Oberlin, Odile

Published
2012
Full Text
View/download PDF

18. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).

Author

Ferrari A, van Noesel MM, Brennan B, Zanetti I, Corradini N, Casanova M, Berlanga P, Merks JHM, Alaggio R, Schifflers S, Ramirez-Villar GL, Giraudo C, Burrieza GG, Safwat A, Bisogno G, De Salvo GL, and Orbach D

Subjects
Adolescent, Chemoradiotherapy, Adjuvant, Child, Disease-Free Survival, Europe, Female, Humans, Male, Neoplasm Staging, Practice Guidelines as Topic standards, Prospective Studies, Sarcoma, Synovial drug therapy, Sarcoma, Synovial radiotherapy, Sarcoma, Synovial surgery, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin administration & dosage, Ifosfamide administration & dosage, Sarcoma drug therapy, Sarcoma radiotherapy, Sarcoma surgery, Soft Tissue Neoplasms drug therapy, Soft Tissue Neoplasms radiotherapy, Soft Tissue Neoplasms surgery
Abstract

Background: A standardised approach to treatment of paediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS), which account for about 4% of childhood cancers, is still lacking. We report the results of the NRSTS 2005 protocol developed specifically by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) to determine a risk-adapted multimodal standard of care for this group of tumours., Methods: The EpSSG NRSTS 2005 study included two prospective, non-randomised, historically controlled trials (one on localised adult-type NRSTS and the other on localised synovial sarcoma) done at 100 academic centres and hospitals in 14 countries. Patients younger than 21 years with a pathologically proven diagnosis of synovial sarcoma or an adult-type NRSTS, no evidence of metastatic disease, no previous treatment other than primary surgery, and diagnostic specimens available for pathological review were included. Patients were stratified by surgical stage, tumour size, nodal involvement, tumour grade (for adult-type NRSTS), and tumour site (for synovial sarcoma). Patients were then divided into four treatment groups: surgery alone, adjuvant radiotherapy, adjuvant chemotherapy (with or without radiotherapy), or neoadjuvant chemotherapy (with or without radiotherapy). The main chemotherapy regimen was ifosfamide (3·0 g/m 2 intravenously per day for 3 days) plus doxorubicin (37·5 mg/m 2 intravenously per day for 2 days); only ifosfamide (3·0 g/m 2 intravenously per day for 2 days) was given concomitantly with radiotherapy (delivered with three-dimensional conformal external beam technique, using conventional fractionation [1·8 daily fractions, 5 days per week] at a dose of 50·4 Gy or 54·0 Gy, to a maximum of 59·4 Gy). The number of chemotherapy cycles ranged from three to seven depending on the stage of the disease. The primary outcomes were event-free survival and overall survival. This study has been completed, and is registered under EudraCT, 2005-001139-31., Findings: Between May 31, 2005, and Dec 31, 2016, 1321 patients were enrolled, of whom 569 (206 with synovial sarcoma and 363 with adult-type NRSTS), with a median age of 12·6 years (IQR 8·2-14·9), were included in this analysis. With a median follow-up of 80·0 months (IQR 54·3-111·3) for the 467 patients alive, 5-year event-free survival was 73·7% (95% CI 69·7-77·2) and 5-year overall survival was 83·8% (95% CI 80·3-86·7). 5-year event-free survival was 91·4% (95% CI 87·0-94·4) and 5-year overall survival was 98·1% (95% CI 95·0-99·3) in the surgery alone group (n=250); 75·5% (46·9-90·1) and 88·2% (60·6-96·9) in the adjuvant radiotherapy group (n=17); 65·6% (54·8-74·5) and 75·8% (65·3-83·5) in the adjuvant chemotherapy group (n=93); and 56·4% (49·3-63·0) and 70·4% (63·3-76·4) in the neoadjuvant chemotherapy group (n=209). Reported severe adverse events included one case of generalised seizures (probably related to ifosfamide) and six cases of secondary tumours., Interpretation: Findings from the EpSSG NRSTS 2005 study help to define the risk-adapted standard of care for this patient population. Adjuvant treatment can be safely omitted in the low-risk population (classified here as the surgery alone group). Improving the outcome for patients with high-risk, initially resected adult-type NRSTS and those with initially unresectable disease remains a major clinical challenge., Funding: Fondazione Città della Speranza., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)

Published
2021
Full Text
View/download PDF

19. The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series.

Author

Orbach D, Brennan B, Bisogno G, Van Noesel M, Minard-Colin V, Daragjati J, Casanova M, Corradini N, Zanetti I, De Salvo GL, Defachelles AS, Kelsey A, Arush MB, Francotte N, and Ferrari A

Abstract

Background: In 2005, the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) proposed a conservative treatment algorithm-consisting of an initial wait-and-see strategy, non-mutilating surgery, and minimal-morbidity chemotherapy (in the case of tumour progression)-for paediatric patients with desmoid-type fibromatosis. We aimed to investigate the outcomes of this algorithm., Methods: In this case series, patients (<25 years) with desmoid-type fibromatosis from 57 centres in eight countries were prospectively registered through a web-based system. Diagnosis was based on histological analysis of the tumour specimen after biopsy or surgery, and we classified patients by tumour site, clinical stage (TNM system), and post-surgical stage (Intergroup Rhabdomyosarcoma Study system). Progression-free survival was defined as the time from diagnosis until disease progression (clinical or radiological progressive disease, relapse, or death from any cause)., Findings: From Oct 1, 2005, to July 31, 2016, 173 patients (median age 11·4 years [IQR 4·0-14·1], 88 [51%] male patients) were registered. After excluding patients with missing data, 54 (35%) patients had no immediate therapy (wait-and-see strategy), 47 (31%) had immediate surgery, and 53 (34%) had immediate chemotherapy after diagnosis. 5-year progression-free survival was 36·5% (95% CI 27·8-45·2) overall, 26·7% (14·2-41·0) in the wait-and-see group, 41·2% (25·8-55·9) in the surgery group, and 42·8% (27·2-57·6) in the chemotherapy group (overall log-rank p=0·17; wait-and-see vs surgery p=0·12; wait-and-see vs chemotherapy p=0·13). In multivariable analysis, large tumour size (>5 cm) was associated with worse progression-free survival (hazard ratio 2·25, 95% CI 1·34-3·76; p=0·0021). Apart from one patient in the chemotherapy group who died from a secondary tumour (head and neck anaplastic embryonal rhabdomyosarcoma), all patients were alive at the time of analysis. 13 (8%) patients had biopsy only (no further treatment), 65 (42%) had chemotherapy only, 31 (20%) had surgery only, 36 (23%) had both chemotherapy and surgery, and nine (6%) had radiotherapy in addition to other therapies., Interpretation: In paediatric patients with desmoid-type fibromatosis, the EpSSG conservative strategy did not compromise outcomes and could be adopted to reduce treatment burden., Funding: S Wisnia and la Città della Speranza Foundation., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results